![EMA recalls heart medicine valsartan made by Chinese firm over potential cancer-causing residue | Fierce Pharma EMA recalls heart medicine valsartan made by Chinese firm over potential cancer-causing residue | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1531152084/headache-1540220_1920.jpg/headache-1540220_1920.jpg?VersionId=3YnhGpZV8h.vn0ITyc2BgCX2gs3NXmeT)
EMA recalls heart medicine valsartan made by Chinese firm over potential cancer-causing residue | Fierce Pharma
![Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA](https://www.fda.gov/files/styles/recall_image_small/public/6_0.jpg?itok=6s3suAz7)
Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of all Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets that are Within Expiry | FDA
![Novartis v. Teva: Patent rivalries meet again, this time on a non-negligible injunction. - The IPKat Novartis v. Teva: Patent rivalries meet again, this time on a non-negligible injunction. - The IPKat](https://2.bp.blogspot.com/-sRfK6UDUTRQ/WzZsaQocDqI/AAAAAAAAADY/1jzaJ_0n7RYxh_vgSs5lJxPkH3rl_3ovgCLcBGAs/s1600/Exforge-Tablets-5mg_80mg-Front.png)